Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, de Gislain C, Pouillart P, Delozier T, Luporsi E, Etienne PL, Schraub S, Eymard JC, Serin D, Ganem G, Calais G, Maillart P, Colin P, Trillet-Lenoir V, Prevost G, Tigaud D, Clavère P, Marti P, Romieu G, Wendling JL.
Namer M, et al. Among authors: wendling jl.
Eur J Cancer. 2001 Jun;37(9):1132-40. doi: 10.1016/s0959-8049(01)00093-4.
Eur J Cancer. 2001.
PMID: 11378344
Clinical Trial.